Viatris' Ryzumvi wins FDA label expansion to presbyopia

Viatris received FDA approval to expand the label of its ophthalmic drug Ryzumvi to treat presbyopia, based on positive Phase III clinical trial results. This indication complements the previously approved use of Ryzumvi for reversing pharmacologically induced mydriasis and positions it against AbbVie's Vuity with a distinct mechanism of action.

This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 17 Oct 2026 and 19 Oct 2026.